⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25899376 | 0.89 | — | — | |
| SCHEMBL22762085 | 0.87 | — | — | |
| SCHEMBL22762088 | 0.85 | — | — | |
| SCHEMBL22767775 | 0.85 | — | — | |
| SCHEMBL22761994 | 0.85 | — | — | |
| SCHEMBL25899277 | 0.82 | — | — | |
| SCHEMBL22762009 | 0.78 | — | — | |
| SCHEMBL22762008 | 0.78 | — | — | |
| SCHEMBL22762011 | 0.76 | — | — | |
| SCHEMBL22762010 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-114375296-A | Nucleic acid polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3980436-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| WO-2020247782-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |